Modelo estratégico integral para el progreso de salud ocupacional (SG-SST) para la empresa Bancolombia

El programa de Seguridad y Salud en el trabajo es una herramienta valiosa, que le permite a las empresas hoy en día la planeación, organización ejecución y evaluación de las actividades de la Medicina Preventiva y del Trabajo, Higiene y Seguridad Industrial, inclinadas en proteger, mantener y mejorar la salud de los trabajadores en sus labores y que deben ser desarrolladas en sus sitios de trabajo en forma integral e interdisciplinaria En este sentido, el grupo Bancolombia, a través del SG-SST, procura que la detección de estos daños a la salud sea clave fundamental, y que su comunicación también, al permitir que se puedan investigar y adoptar las medidas preventivas necesarias para evitar su progresión en el caso concreto y también que se produzcan nuevos casos. Es por ello importante que la implementación del SG-SST, involucre como partes interesadas, aquellas que tengan influencia o impacto en el desempeño de la organización, como lo son: clientes, empleados, socios, proveedores y autoridades legales y de control, quienes deben tener como requisito la planificación y desarrollo de los procesos y actividades que interactúan con los mismos, al igual que su seguimiento y revisión de información.The Occupational Health and Safety program is a valuable tool that allows companies today to plan, organize, execute and evaluate the activities of Preventive Medicine and Labor, Hygiene and Industrial Safety, inclined to protect , maintain and improve the health of workers in their work and that must be developed in their workplaces in an integral and interdisciplinary way In this sense, the Bancolombia group, through the SG-SST, seeks to ensure that the detection of these health damages is a fundamental key, and that their communication also, by allowing them to investigate and adopt the necessary preventive measures to avoid their progression in the specific case and also that new It is therefore important that the implementation of the SG-SST, involves as stakeholders, those that have influence or impact on the performance of the organization, such as: customers, employees, partners, suppliers and legal and control authorities, who must have as a requirement the planning and development of the processes and activities that interact with them, as well as their monitoring and review of information

Exploring bovine fecal bacterial microbiota in the Mapimi Biosphere Reserve, Northern Mexico

En México la información sobre la microbiota fecal bovina (Bos taurus) es escasa. El presente estudio describe la diversidad y abundancia de bacterias en muestras fecales de bovinos en pastizales, recolectadas en la Reserva de la Biosfera de Mapimí en la parte central del desierto chihuahuense. Las muestras fecales se analizaron mediante secuenciación masiva de siguiente generación de alto rendimiento utilizando la V3-V4 del ARNr 16S en Miseq de Illumina. Se identificaron un total de 17 filos, 24 clases, 33 órdenes, 50 familias, 281 géneros y 297 especies. Firmicutes y Verrucomicrobia fueron los filos más abundantes. Los géneros más abundantes fueron Sporobacter, PAC000748_g (géneros de la familia Ruminococcaceae) y Eubacterium_g23. Se registraron tres géneros (Clostridium, Corynebacterium y Fusobacterium) y una especie (Campylobacter fetus) de bacterias bovinas potencialmente patógenas. Esta información representa una línea base bacteriológica para monitorear el estado de salud intestinal de bovinos en pastoreo y para rastrear posibles interacciones con la microbiota fecal de la fauna nativa itinerante del área.In Mexico, information on the bovine fecal microbiota (Bos taurus) is scarce. The present study describes the diversity and abundance of bacteria in fecal samples from rangeland bovines, collected in the Mapimi Biosphere Reserve in the central part of the Chihuahuan desert. Fecal samples were analysed using high-throughput next generation massive sequencing using V3-V4 16S rRNA on Illumina Miseq. A total of 17 phyla, 24 classes, 33 orders, 50 families, 281 genera, and 297 species were identified. Firmicutes and Verrucomicrobia were the most abundant phyla. The most abundant genera were Sporobacter, PAC000748_g (genera into the Ruminococcaceae family) and Eubacterium_g23. Three genera (Clostridium, Corynebacterium and Fusobacterium) and one species (Campylobacter fetus) potentially pathogenic bovine bacteria were registered. This information represents a bacteriological baseline for monitoring the grazing bovine intestinal health status, and to trace possible interactions with the fecal microbiota of native roaming wildlife in the area

Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa

BackgroundBacteriophage therapy is becoming part of mainstream Western medicine since antibiotics of clinical use tend to fail. It involves applying lytic bacteriophages that self-replicate and induce cell lysis, thus killing their hosts. Nevertheless, bacterial killing promotes the selection of resistant clones which sometimes may exhibit a decrease in bacterial virulence or antibiotic resistance.MethodsIn this work, we studied the Pseudomonas aeruginosa lytic phage φDCL-PA6 and its variant φDCL-PA6α. Additionally, we characterized and evaluated the production of virulence factors and the virulence in a Galleria mellonella model of resistant mutants against each phage for PA14 and two clinical strains.ResultsPhage φDCL-PA6α differs from the original by only two amino acids: one in the baseplate wedge subunit and another in the tail fiber protein. According to genomic data and cross-resistance experiments, these changes may promote the change of the phage receptor from the O-antigen to the core lipopolysaccharide. Interestingly, the host range of the two phages differs as determined against the Pseudomonas aeruginosa reference strains PA14 and PAO1 and against nine multidrug-resistant isolates from ventilator associated pneumonia.ConclusionsWe show as well that phage resistance impacts virulence factor production. Specifically, phage resistance led to decreased biofilm formation, swarming, and type III secretion; therefore, the virulence towards Galleria mellonella was dramatically attenuated. Furthermore, antibiotic resistance decreased for one clinical strain. Our study highlights important potential advantages of phage therapy’s evolutionary impact that may be exploited to generate robust therapy schemes

Latin American study of hereditary breast and ovarian cancer LACAM : a genomic epidemiology approach

Q2Q1Artículo original1-13Purpose: Hereditary Breast and Ovarian Cancer (HBOC) syndrome is responsible for ~5–10% of all diagnosed breast and ovarian cancers. Breast cancer is the most common malignancy and the leading cause of cancer-related mortality among women in Latin America (LA). The main objective of this study was to develop a comprehensive understanding of the genomic epidemiology of HBOC throughout the establishment of The Latin American consortium for HBOC-LACAM, consisting of specialists from 5 countries in LA and the description of the genomic results from the first phase of the study. Methods: We have recruited 403 individuals that fulfilled the criteria for HBOC from 11 health institutions of Argentina, Colombia, Guatemala, Mexico and Peru. A pilot cohort of 222 individuals was analyzed by NGS gene panels. One hundred forty-three genes were selected on the basis of their putative role in susceptibility to different hereditary cancers. Libraries were sequenced in MiSeq (Illumina, Inc.) and PGM (Ion Torrent-Thermo Fisher Scientific) platforms. Results: The overall prevalence of pathogenic variants was 17% (38/222); the distribution spanned 14 genes and varied by country. The highest relative prevalence of pathogenic variants was found in patients from Argentina (25%, 14/57), followed by Mexico (18%, 12/68), Guatemala (16%, 3/19), and Colombia (13%, 10/78). Pathogenic variants were found in BRCA1 (20%) and BRCA2 (29%) genes. Pathogenic variants were found in other 12 genes, including high and moderate risk genes such as MSH2, MSH6, MUTYH, and PALB2. Additional pathogenic variants were found in HBOC unrelated genes such as DCLRE1C, WRN, PDE11A, and PDGFB. Conclusion: In this first phase of the project, we recruited 403 individuals and evaluated the germline genetic alterations in an initial cohort of 222 patients among 4 countries. Our data show for the first time in LA the distribution of pathogenic variants in a broad set of cancer susceptibility genes in HBOC. Even though we used extended gene panels, there was still a high proportion of patients without any detectable pathogenic variant, which emphasizes the larger, unexplored genetic nature of the disease in these populations

Cancer Genomic Resources and Present Needs in the Latin American Region

In Latin America (LA), cancer is the second leading cause of death, and little is known about the capacities and needs for the development of research in the field of cancer genomics. In order to evaluate the current capacity for and development of cancer genomics in LA, we collected the available information on genomics, including the number of next-generation sequencing (NGS) platforms, the number of cancer research institutions and research groups, publications in the last 10 years, educational programs, and related national cancer control policies. Currently, there are 221 NGS platforms and 118 research groups in LA developing cancer genomics projects. A total of 272 articles in the field of cancer genetics/genomics were published by authors affiliated to Latin American institutions. Educational programs in genomics are scarce, almost exclusive of graduate programs, and only few are concerning cancer. Only 14 countries have national cancer control plans, but all of them consider secondary prevention strategies for early diagnosis, opportune treatment, and decreasing mortality, where genomic analyses could be implemented. Despite recent advances in introducing knowledge about cancer genomics and its application to LA, the region lacks development of integrated genomic research projects, improved use of NGS platforms, implementation of associated educational programs, and health policies that could have an impact on cancer care.Fil: Torres, Ángela. Universidad El Bosque; ColombiaFil: Oliver, Javier. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; ArgentinaFil: Frecha, Cecilia Ariana. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Montealegre, Ana Lorena. Universidad El Bosque; ColombiaFil: Quezada Urbán, Rosalía. Universidad Nacional Autónoma de México; MéxicoFil: Díaz Velásquez, Clara Estela. Universidad Nacional Autónoma de México; MéxicoFil: Vaca Paniagua, Felipe. Universidad Nacional Autónoma de México; México. Instituto Nacional de Cancerología; MéxicoFil: Perdomo, Sandra. Universidad El Bosque; Colombia. Hospital Universitario Fundación Santa Fe; Colombi

Cancer genomic resources and present needs in the latin american region

In Latin America (LA), cancer is the second leading cause of death, and little is known about the capacities and needs for the development of research in the field of cancer genomics. In order to evaluate the current capacity for and development of cancer genomics in LA, we collected the available information on genomics, including the number of next-generation sequencing (NGS) platforms, the number of cancer research institutions and research groups, publications in the last 10 years, educational programs, and related national cancer control policies. Currently, there are 221 NGS platforms and 118 research groups in LA developing cancer genomics projects. A total of 272 articles in the field of cancer genetics/genomics were published by authors affiliated to Latin American institutions. Educational programs in genomics are scarce, almost exclusive of graduate programs, and only few are concerning cancer. Only 14 countries have national cancer control plans, but all of them consider secondary prevention strategies for early diagnosis, opportune treatment, and decreasing mortality, where genomic analyses could be implemented. Despite recent advances in introducing knowledge about cancer genomics and its application to LA, the region lacks development of integrated genomic research projects, improved use of NGS platforms, implementation of associated educational programs, and health policies that could have an impact on cancer care

Activation parameters of Ca_V3.3, Ca_V1.2 and chimeric channels.

<p>Activation parameters of Ca_V3.3, Ca_V1.2 and chimeric channels.</p

Mutagenesis in Domain II reveals a participation of the S4-S5 linker in the LVA behavior of Ca_V3.3 channels.

<p><b><i>A</i></b>, examples of calcium currents generated by the indicated channels. Holding potential was -100 mV, and current recordings were obtained at -30 mV for Ca_V3.3-WT and Q716A, and at -20 mV for P711A and RRQ714SNL. <b><i>B</i></b>, <i>I-V</i> relationships. Current density was calculated for each cell, averaged, and plotted as a function of test potential. <b><i>C</i></b>, normalized <i>I-V</i> curves for inward currents. Data were fitted with a modified Boltzmann function (continuous line). Same cells as shown in <b><i>B</i></b>. <b><i>D</i></b>, steady-state inactivation curves for WT and the indicated Ca_V3.3 mutants. Smooth lines are fits to Boltzmann functions. <b><i>E</i></b>, time course of recovery from inactivation at -100 mV for the indicated Ca_V3.3 channels. Data was analyzed and plotted as indicated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193490#pone.0193490.g005" target="_blank">Fig 5</a>. <b><i>F</i></b>, deactivation time constants for channel closing as a function of the repolarizing potential. Data in graphs represent mean ± SEM. Parameter and tau values, number of cells and statistical significance are shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193490#pone.0193490.t003" target="_blank">Table 3</a>.</p

Steady-state inactivation parameters of Ca_V3.3, Ca_V1.2 and chimeric channels.

<p>Steady-state inactivation parameters of Ca_V3.3, Ca_V1.2 and chimeric channels.</p